These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 7939432)

  • 21. In vitro activity of the siderophore monosulfactam BAL30072 against contemporary Gram-negative pathogens from New York City, including multidrug-resistant isolates.
    Landman D; Singh M; El-Imad B; Miller E; Win T; Quale J
    Int J Antimicrob Agents; 2014 Jun; 43(6):527-32. PubMed ID: 24796217
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative bactericidal activity of fluoroquinolones against clinical isolates resistant to fluoroquinolones.
    Drago L; De Vecchi E; Nicola L; Valli M; Marchetti F; Gismondo MR
    J Chemother; 2003 Apr; 15(2):118-23. PubMed ID: 12797386
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [In vitro activity of 4 fluoroquinolones against Klebsiella pneumoniae. Distribution according to phenotype resistance to aminoglycosides or beta-lactams].
    Miguères ML; Ronco E; Guenounou M
    Pathol Biol (Paris); 1990 May; 38(5):385-9. PubMed ID: 2195447
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro potency of amikacin and comparators against E. coli, K. pneumoniae and P. aeruginosa respiratory and blood isolates.
    Sutherland CA; Verastegui JE; Nicolau DP
    Ann Clin Microbiol Antimicrob; 2016 Jun; 15(1):39. PubMed ID: 27316973
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro activity of sparfloxacin (CI-978), a new broad-spectrum fluoroquinolone.
    Qadri SM; Ueno Y; Burns JJ; Almodovar E; Rabea N
    Chemotherapy; 1992; 38(2):99-106. PubMed ID: 1317282
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Distribution of biocide resistant genes and biocides susceptibility in multidrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii - A first report from the Kingdom of Saudi Arabia.
    Vijayakumar R; Sandle T; Al-Aboody MS; AlFonaisan MK; Alturaiki W; Mickymaray S; Premanathan M; Alsagaby SA
    J Infect Public Health; 2018; 11(6):812-816. PubMed ID: 29907439
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Post-antibiotic effect of quinolones on Pseudomonas aeruginosa.
    Sood P; Mandal A; Mishra B
    J Antimicrob Chemother; 1999 Mar; 43(3):425-7. PubMed ID: 10223604
    [No Abstract]   [Full Text] [Related]  

  • 28. Quinolone resistance. Susceptibility data from a 300-bed community hospital.
    Parry MF; Panzer KB; Yukna ME
    Am J Med; 1989 Nov; 87(5A):12S-16S. PubMed ID: 2511756
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens.
    Hansen GT; Blondeau JM
    J Chemother; 2005 Oct; 17(5):484-92. PubMed ID: 16323436
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative antimicrobial activity of enoxacin, ciprofloxacin, amifloxacin, norfloxacin and ofloxacin against 177 bacterial isolates.
    Bassey CM; Baltch AL; Smith RP
    J Antimicrob Chemother; 1986 May; 17(5):623-8. PubMed ID: 2941401
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Investigation of antimicrobial resistance of Klebsiella pneumoniae and Pseudomonas aeruginosa isolates from rat-like animals around a hospital in Guangzhou].
    Zhong XS; Ge J; Chen SW; Xiong YQ; Zheng XY; Qiu M; Huo ST; Chen Q
    Nan Fang Yi Ke Da Xue Xue Bao; 2016 May; 36(5):688-92. PubMed ID: 27222186
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The pharmacodynamics and pharmacokinetics of fluoroquinolones in the evaluation of antibacterial therapy regimens].
    Smirnova LB; Sokolova VI
    Antibiot Khimioter; 2000; 45(7):14-6. PubMed ID: 10987102
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Activity of 5 fluoroquinolones on hospital Gram-negative bacilli with different sensitivities to pefloxacin].
    Aubert G; Puech C; Lucht F; Loboguerrero M; Denis M; Dorche G
    Pathol Biol (Paris); 1989 Oct; 37(8):881-7. PubMed ID: 2515519
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Antimicrobial susceptibility pattern of nosocomial gram negative pathogens: results from MYSTIC study in Hacettepe University Adult Hospital (2000-2004)].
    Zarakolu P; Hasçelik G; Unal S
    Mikrobiyol Bul; 2006 Jul; 40(3):147-54. PubMed ID: 17001842
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Susceptibility of 570 Pseudomonas aeruginosa strains to 11 antimicrobial agents and the mechanism of its resistance to fluoroquinolones].
    Lei YC; Wang HB; Sun ZY; Shen ZY
    Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):403-7. PubMed ID: 12820918
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (1996)].
    Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Shimizu Y; Terai T; Inoue H; Nakadate T; Ito C; Yoshida T; Ohno I; Tanno Y; Arakawa M; Igarashi K; Okada M; Ozaki K; Aoki N; Kitamura N; Sekine O; Suzuki Y; Nakata K; Nakatani T; Inagawa H; Kusano N
    Jpn J Antibiot; 1998 Jul; 51(7):437-74. PubMed ID: 9755430
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the in vitro susceptibility and emergence of mutants resistant to ciprofloxacin among multidrug resistant clinical isolates.
    Lopes CA; Mendes RP; Curi PC; Watanabe DS; Decarlis RM; Horácio A; Michelin LA; Placidelli BA
    Rev Latinoam Microbiol; 1993; 35(4):345-9. PubMed ID: 8066328
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction of resistance of Streptococcus pneumoniae to quinolones in vitro.
    Lafredo SC; Foleno BD; Fu KP
    Chemotherapy; 1993; 39(1):36-9. PubMed ID: 8383031
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Energy-dependent accumulation of fluoroquinolones in quinolone-resistant Klebsiella pneumoniae strains.
    Martínez-Martínez L; García I; Ballesta S; Benedí VJ; Hernández-Allés S; Pascual A
    Antimicrob Agents Chemother; 1998 Jul; 42(7):1850-2. PubMed ID: 9661034
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of resistance to nalidixic acid and the fluoroquinolones after the introduction of norfloxacin and ofloxacin.
    Kresken M; Wiedemann B
    Antimicrob Agents Chemother; 1988 Aug; 32(8):1285-8. PubMed ID: 3142353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.